137家药企年报预亏，亏损最高的超百亿

Core Viewpoint - The pharmaceutical sector in A-shares is facing significant losses, with 137 companies forecasting losses for 2025, primarily due to declining product prices and increased competition [2][3][8]. Group 1: Loss Forecasts - Among the 137 companies, the largest projected loss is from Zhifei Biological Products, with an expected net loss of up to 13.726 billion yuan [5]. - Other notable companies with significant losses include Zhenbaodao (1.173 billion yuan), Baili Tianheng (1.1 billion yuan), and several others with losses exceeding 500 million yuan [5]. - The losses are attributed to various factors, including delayed customer payments, inventory devaluation, increased R&D costs, and changes in tax policies [5][6]. Group 2: Price Declines and Market Competition - A major factor contributing to the losses is the decline in product prices, which has been mentioned by at least 30 companies [8]. - Companies like Wantai Biological Pharmacy are experiencing losses due to competitive pressures and price reductions in the HPV vaccine market, with an expected loss of up to 410 million yuan [9]. - Other companies, such as Shuanglu Pharmaceutical and Guangji Pharmaceutical, have also reported losses due to prolonged low sales prices and increased market competition [10][11]. Group 3: Impact of Policy Changes - The centralized procurement policies in the pharmaceutical industry are squeezing profit margins, leading to significant price reductions for many products [10]. - Companies like Zhenbaodao and Wanbangde have reported substantial revenue declines due to policy adjustments and increased competition in the market [10][11]. - The impact of these policies is evident in the overall market, where companies are forced to lower prices to remain competitive, resulting in reduced profit margins [10][11]. Group 4: Strategic Responses - In response to the challenges, companies are optimizing their operational strategies, including adjusting procurement plans and enhancing product promotion strategies [6]. - Some firms are also exploring transitions from generic drug manufacturing to innovative drug development and expanding into overseas markets to mitigate domestic competition [12].